Low ficolin-3 levels in early follow-up serum samples are associated with the severity and unfavorable outcome of acute ischemic stroke

Journal of Neuroinflammation

Peter Garred⁶  Mikkel-Ole Skjoedt⁶  Zoltán Prohászka¹  Zoltán Széplaki³  Robert Szegedi³  Kristóf Hirschberg⁴  Gabriella Pusch⁵  Tihamér Molnar²  Gábor Széplaki¹  Zsolt Illes⁵  Lea Munthe-Fog⁶  George Füst¹ 

[1] 3rd Department of Internal Medicine, Semmelwies University, Budapest, Hungary;Institute of Anaesthesia and Intensive Therapy, Faculty of Medicine, University of Pecs, Pecs, Hungary;Department of Neurology, Kútvölgyi Clinical Centre, Semmelweis University, Budapest, Hungary;Experimental Laboratory of Cardiac Surgery, University of Heidelberg, Germany;Division of Clinical and Experimental Neuroimmunology, Department of Neurology, University of Pecs, Pecs, Hungary;Laboratory of Molecular Medicine, Department of Clinical Immunology-7631, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

关键词: CRP;    ficolin-3;    ficolin-2;    ficolins;    lectin pathway;    complement;    outcome;    ischemic stroke;    stroke;   

Others  :  1212916
DOI  :  10.1186/1742-2094-8-185

 received in 2011-09-07, accepted in 2011-12-29,  发布年份 2011

【 摘 要 】

Background

A number of data indicate that the lectin pathway of complement activation contributes to the pathophysiology of ischemic stroke. The lectin pathway may be triggered by the binding of mannose-binding lectin (MBL), ficolin-2 or ficolin-3 to different ligands. Although several papers demonstrated the significance of MBL in ischemic stroke, the role of ficolins has not been examined.

Methods

Sera were obtained within 12 hours after the onset of ischemic stroke (admission samples) and 3-4 days later (follow-up samples) from 65 patients. The control group comprised 100 healthy individuals and 135 patients with significant carotid stenosis (patient controls). The concentrations of ficolin-2 and ficolin-3, initiator molecules of the lectin complement pathway, were measured by ELISA methods. Concentration of C-reactive protein (CRP) was also determined by a particle-enhanced immunturbidimetric assay.

Results

Concentrations of both ficolin-2 and ficolin-3 were significantly (p < 0.001) decreased in both the admission and in the follow-up samples of patients with definite ischemic stroke as compared to healthy subjects. Concentrations of ficolin-2 and ficolin-3 were even higher in patient controls than in healthy subjects, indicating that the decreased levels in sera during the acute phase of stroke are related to the acute ischemic event. Ficolin-3 levels in the follow-up samples inversely correlated with the severity of stroke indicated by NIH scale on admission. In follow-up samples an inverse correlation was observed between ficolin-3 levels and concentration of S100β, an indicator of the size of cerebral infarct. Patients with low ficolin-3 levels and high CRP levels in the follow up samples had a significantly worse outcome (adjusted ORs 5.6 and 3.9, respectively) as measured by the modified Rankin scale compared to patients with higher ficolin-3 and lower CRP concentrations. High CRP concentrations were similarly predictive for worse outcome, and the effects of low ficolin-3 and high CRP were independent.

Conclusions

Our findings indicate that ficolin-mediated lectin pathways of complement activation contribute to the pathogenesis of ischemic stroke and may be additive to complement-independent inflammatory processes.

【 授权许可】

   
2011 Füst et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ceulemans AG, Zgavc T, Kooijman R, Hachimi-Idrissi S, Sarre S, Michotte Y: The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia. J Neuroinflammation 2010, 7:74. BioMed Central Full Text
• [2]Yanamadala V, Friedlander RM: Complement in neuroprotection and neurodegeneration. Trends Mol Med 2010, 16:69-76.
• [3]Szeplaki G, Szegedi R, Hirschberg K, et al.: Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis 2009, 204:315-320.
• [4]Cervera A, Planas AM, Justicia C, et al.: Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS One 2010, 5:e8433.
• [5]Mocco J, Sughrue ME, Ducruet AF, Komotar RJ, Sosunov SA, Connolly ES Jr: The complement system: a potential target for stroke therapy. Adv Exp Med Biol 2006, 586:189-201.
• [6]Ducruet AF, Zacharia BE, Hickman ZL, et al.: The complement cascade as a therapeutic target in intracerebral hemorrhage. Exp Neurol 2009, 219:398-403.
• [7]D'Ambrosio AL, Pinsky DJ, Connolly ES: The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection. Mol Med 2001, 7:367-382.
• [8]Nishino H, Czurko A, Fukuda A, et al.: Pathophysiological process after transient ischemia of the middle cerebral artery in the rat. Brain Res Bull 1994, 35:51-56.
• [9]Van Beek J, Bernaudin M, Petit E, et al.: Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol 2000, 161:373-382.
• [10]Huang J, Kim LJ, Mealey R, et al.: Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 1999, 285:595-599.
• [11]Pedersen ED, Froyland E, Kvissel AK, et al.: Expression of complement regulators and receptors on human NT2-N neurons--effect of hypoxia and reoxygenation. Mol Immunol 2007, 44:2459-2468.
• [12]Mocco J, Mack WJ, Ducruet AF, et al.: Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res 2006, 99:209-217.
• [13]Atkinson C, Zhu H, Qiao F, et al.: Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol 2006, 177:7266-7274.
• [14]Arumugam TV, Tang SC, Lathia JD, et al.: Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci USA 2007, 104:14104-14109.
• [15]Harhausen D, Khojasteh U, Stahel PF, et al.: Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice. J Neuroinflammation 2010, 7:15. BioMed Central Full Text
• [16]Vasthare US, Barone FC, Sarau HM, et al.: Complement depletion improves neurological function in cerebral ischemia. Brain Res Bull 1998, 45:413-419.
• [17]Figueroa E, Gordon LE, Feldhoff PW, Lassiter HA: The administration of cobra venom factor reduces post-ischemic cerebral injury in adult and neonatal rats. Neurosci Lett 2005, 380:48-53.
• [18]Akita N, Nakase H, Kaido T, Kanemoto Y, Sakaki T: Protective effect of C1 esterase inhibitor on reperfusion injury in the rat middle cerebral artery occlusion model. Neurosurgery 2003, 52:395-400.
• [19]De Simoni MG, Storini C, Barba M, et al.: Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J Cereb Blood Flow Metab 2003, 23:232-239.
• [20]Gesuete R, Storini C, Fantin A, et al.: Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol 2009, 66:332-342.
• [21]Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE: Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol 2004, 137:117-122.
• [22]Mocco J, Wilson DA, Komotar RJ, et al.: Alterations in plasma complement levels after human ischemic stroke. Neurosurgery 2006, 59:28-33.
• [23]Osthoff M, Katan M, Fluri F, et al.: Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PLoS One 2011, 6:e21338.
• [24]Orsini F, Parrella S, Villa P, et al.: Mannose binding lectin as a target for cerebral ischemic injury. Molecular Immunology 2011, 48:1677.
• [25]Garred P, Honore C, Ma YJ, et al.: The genetics of ficolins. J Innate Immun 2009, 2:3-16.
• [26]Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M: Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005, 62:1130-1134.
• [27]Molnar T, Papp V, Banati M, et al.: Relationship between C-reactive protein and early activation of leukocytes indicated by leukocyte antisedimentation rate (LAR) in patients with acute cerebrovascular events. Clin Hemorheol Microcirc 2010, 44:183-192.
• [28]Di Napoli M, Schwaninger M, Cappelli R, et al.: Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 2005, 36:1316-1329.
• [29]Song IU, Kim YD, Kim JS, Lee KS, Chung SW: Can high-sensitivity C-reactive protein and plasma homocysteine levels independently predict the prognosis of patients with functional disability after first-ever ischemic stroke? Eur Neurol 2010, 64:304-310.
• [30]Youn CS, Choi SP, Kim SH, et al.: Serum highly selective C-reactive protein concentration is associated with the volume of ischemic tissue in acute ischemic stroke. The American journal of emergency medicine 2010, 30(1):124-8.
• [31]Ormstad H, Aass HC, Lund-Sorensen N, Amthor KF, Sandvik L: Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. Journal of neurology 2011, 258:677-685.
• [32]Adams RJ, Albers G, Alberts MJ, et al.: Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008, 39:1647-1652.
• [33]Cohen J, Brun-Buisson C, Torres A, Jorgensen J: Diagnosis of infection in sepsis: an evidence-based review. Critical care medicine 2004, 32:S466-494.
• [34]Brott T, Adams HP Jr, Olinger CP, et al.: Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989, 20:864-870.
• [35]Bonita R, Beaglehole R: Recovery of motor function after stroke. Stroke 1988, 19:1497-1500.
• [36]Munthe-Fog L, Hummelshoj T, Hansen BE, et al.: The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand J Immunol 2007, 65:383-392.
• [37]Munthe-Fog L, Hummelshoj T, Ma YJ, et al.: Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. Mol Immunol 2008, 45:2660-2666.
• [38]Sallenbach S, Thiel S, Aebi C, et al.: Serum concentrations of lectin-pathway components in healthy neonates, children and adults: mannan-binding lectin (MBL), M-, L-, and H-ficolin, and MBL-associated serine protease-2 (MASP-2). Pediatr Allergy Immunol 2011, 22(4):424-30.
• [39]Jensen ML, Honore C, Hummelshoj T, Hansen BE, Madsen HO, Garred P: Ficolin-2 recognizes DNA and participates in the clearance of dying host cells. Mol Immunol 2007, 44:856-865.
• [40]Wang CC, Yim KW, Poon TC, et al.: Innate immune response by ficolin binding in apoptotic placenta is associated with the clinical syndrome of preeclampsia. Clin Chem 2007, 53:42-52.
• [41]Beer C, Blacker D, Bynevelt M, Hankey GJ, Puddey IB: Systemic markers of inflammation are independently associated with S100B concentration: results of an observational study in subjects with acute ischaemic stroke. J Neuroinflammation 2010, 7:71. BioMed Central Full Text
• [42]Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ: Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000, 31:2670-2677.
• [43]Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR: Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 2006, 37:2508-2513.
• [44]Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC: Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 2009, 40:77-85.
• [45]Hummelshoj T, Fog LM, Madsen HO, Sim RB, Garred P: Comparative study of the human ficolins reveals unique features of Ficolin-3 (Hakata antigen). Mol Immunol 2008, 45:1623-1632.
• [46]Di Napoli M: Systemic complement activation in ischemic stroke. Stroke 2001, 32:1443-1448.
• [47]Elkind MS, Tai W, Coates K, Paik MC, Sacco RL: High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006, 166:2073-2080.
• [48]Youssef MY, Mojiminiyi OA, Abdella NA: Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease. Transl Res 2007, 150:158-163.
• [49]Cicardi M, Zanichelli A: Replacement therapy with C1 esterase inhibitors for hereditary angioedema. Drugs Today (Barc) 2010, 46:867-874.
• [50]Schrezenmeier H, Hochsmann B: Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria. Expert Rev Hematol 2009, 2:7-16.
• [51]Emlen W, Li W, Kirschfink M: Therapeutic complement inhibition: new developments. Semin Thromb Hemost 2010, 36:660-668.